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Pemetrexed-Induced Typhlitis in Non-small Cell
Lung Cancer
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Abstract: Pemetrexed is U.S. Food and Drug Administration-
approved as a second line, single-agent treatment of recurrent
metastatic non-small cell lung cancer. Gastrointestinal side effects,
including stomatitis, diarrhea, and vomiting are reported to be less
than 1% and rarely severe. In the premetrexed clinical trial database
of 1327 patients, various types of colitis were reported by a total of
nine patients (0.6%). Typhilitis is a gastrointestinal complication of
chemotherapy, which presents as fever and abdominal pain. The
diagnosis is supported by the findings of bowel wall thickening on
computed tomographic imaging. Typhilitis is usually seen in the
setting of severe chemotherapy-induced neutropenia for acute leu-
kemia. Nevertheless, it is increasingly recognized as a complication
of therapy in solid tumors. We present the first documented case of
typhilitis after treatment with pemetrexed and successful therapy
with supportive treatment.
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Pemetrexed is a multitargeted antifolate agent approved in2004 for recurrent non-small cell lung cancer (NSCLC)
after prior platinum based chemotherapy.1 Pemetrexed also
has been shown to be effective in other solid tumors, includ-
ing breast, mesothelioma, colorectal, pancreatic, gastric,
bladder, cervix, and head and neck.2 In a large phase III study
involving 571 patients with advanced NSCLC, premetrexed
was compared with docetaxel and shown to have similar
response rates (9.1 versus 8.8%) and disease stabilization
(45.8 versus 46.4%), but a better safety profile.3 Patients in
the pemetrexed group had lower rates of neutropenia and
neutropenia-related fever, infections, and alopecia. The inci-
dence of gastrointestinal side effects was reported to be less
than 1% and included nausea, vomiting, stomatitis, and diar-
rhea.3 None of the patients developed life-threatening gastro-
intestinal toxicities. We present a case of typhlitis occurring
after a single course of pemetrexed in the setting of second-
line therapy for advanced NSCLC.
CASE REPORT
The patient was a 42-year-old African American
woman with stage IV adenocarcinoma of the lung with
bronchioloalveolar features. She was a never-smoker. The
patient was initially treated on a clinical trial using carbopla-
tin, area under curve of 6, paclitaxel at 200 mg/m2, and
erlotinib 150 mg orally daily. Because of persistent neutro-
penia, she was removed from cytotoxic therapy after the first
cycle. Following disease progression, 16 months later, she
received pemetrexed, 500 mg/m2. Two days after her first
treatment, she presented with a complaint of inability to
tolerate oral intake secondary to severe nausea and vomiting.
She had a low-grade temperature of 99.8°F, sinus tachycar-
dia, diffuse abdominal tenderness to palpation without re-
bound, or guarding. Serum chemistries were unremarkable.
Her white blood count was 3800/L with an absolute
neutrophil count of 1580. Her liver function panel was sig-
nificant for isolated alanine aminotransferase elevation to 140
U/I (normal 10–59 U/I). She was admitted to the hospital,
maintained on NPO (nothing by mouth) status, and treated
with intravenous fluids and antiemetics. During the first 3
days, she improved and was able to tolerate a clear liquid diet
and subsequently a regular diet. Nevertheless, on hospital day
5, she developed right lower quadrant abdominal pain with
marked tenderness to palpation, rebound, and intermittent
guarding. On hospital day 6, the patient developed fever up to
102°F. Her white blood count was 3800/L with absolute
neutrophil count of 1550/L.
She was started on piperacillin/tazobactam and vanco-
mycin empirically, and blood cultures were drawn, but no
growth was subsequently detected. A computed tomographic
(CT) scan of the abdomen with contrast revealed portal
venous air, bowel wall thickening in the cecum, ascending
and transverse colon, and pneumatosis in the transverse colon
consistent with typhlitis (Figure 1). Surgical evaluation rec-
ommended continuation of conservative treatment. Her ab-
dominal pain and nausea improved slowly over the next 3
days. Stools were negative for Clostridium difficile toxin.
Blood cultures, stool, and urine cultures were all negative.
She continued to receive folate at 1 mg orally daily through-
out her hospital course. She had received a vitamin B12
injection before initiation of pemetrexed. A follow-up CT
scan 2 weeks later demonstrated interval resolution of portal
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venous gas and near-complete resolution of transverse and
cecal wall thickening from typhlitis (Figure 2).
PREMETREXED AND TYPHLITIS
Typhlitis is a life-threatening abdominal complication
in the febrile neutropenic patient. It is secondary to a com-
bination of early, yet profound neutropenia and direct toxicity
to the intestinal mucosa by the chemotherapy agents, which
permit invasion of bacteria through the bowel wall.4,5 Neutro-
penia precludes the host from halting bacterial proliferation.
Rampant production of endotoxins leads to further ischemia,
ulceration, and necrosis of the bowel wall. Also termed neutro-
penic enterocolitis, typhlitis is characterized by necrotizing co-
litis afflicting ileum, cecum, ascending colon, and appendix. The
cecum is a blind pouch with poor arterial perfusion directly
exposed to colonic bacteria, and it is particularly prone to
typhlitis. The combination of fever and right-sided abdominal
pain in a cancer patient recently exposed to chemotherapy is
highly concerning for typhlitis. Bowel wall thickening by ultra-
sound or CT is a key criterion for neutropenic enterocolitis.6
Pathology and plain x-ray films are not necessary for diagnosis.
Typhlitis was initially described in 1970 as a life-
threatening condition in children with leukemia and for years
was believed to be limited to leukemia or aplastic anemia
patients. With the advent of new chemotherapy agents, a
growing number of cases of typhlitis have been reported in
neutropenic adults with solid tumors who received chemo-
therapy. In review of 21 cohort studies by Gorschlu¨ter et al.,6
the averaged incidence of typhlitis in adults with hematologic
malignancies, aplastic anemia, or solid tumors after high-dose
chemotherapy was 5.3%. The incidence was similar in a
subgroup of patients with acute leukemias (5.6%), suggesting
that patients with leukemias and solid malignancies are
equally likely to develop typhlitis.
A literature search using “lung,” “typhlitis,” “neutropenic
colitis,” “enterocolitis,” and “solid tumors,” revealed only ten
cases of neutropenic colitis complicating chemotherapy for lung
FIGURE 1. CT abdomen showing (A) thick-
ened wall of large bowel with surrounding fat
stranding (circled) and (B) pneumatosis (circle
and arrow).
FIGURE 2. A follow-up CT scan showing res-
olution of (A) bowel wall thickening and (B)
pneumatosis.
TABLE 1. Summary of Case Reports of Typhlitis in Lung
or Other Thoracic Malignancy in a Setting of Chemotherapy-
Induced Neutropenia
Author
Patient
Characteristics
(Age/Sex) Primary Malignancy
Keidan et al.8 Not specified Small cell lung, esophageal
Millward et al.9 Not specified NSCLC
Lev and Sweeney10 51/M Mesothelioma
Abbasoglu
and Cakmakci11
70/M Lung carcinoma (type not specified)
Stein et al.12 62/F Small cell lung
Avigan et al.13 49/M Small cell lung
Ferrazzí et al.14 50/M Adenocarcinoma of the lung
Cardenal et al.15 46/M Squamous cell carcinoma of the lung
Miller et al.16 Not specified Small cell lung cancer
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and thoracic cancer (Table 1).7–13 No similar cases have been
reported to Eli Lilly Oncology, the manufacturer of pemetrexed
(S. Barker, E. Lilly, Oncology, personal communication, 2006).
CONCLUSION
Typhlitis is being seen more frequently as a serious
complication of aggressive chemotherapy used for treatment
of solid tumors. It may rapidly evolve from abdominal pain
and low-grade fever to hemodynamic instability and bowel
perforation. With the mortality of 50 to 100%,6 early imag-
ing, aggressive treatment, and consideration of surgical treat-
ment such as right hemicolectomy are of paramount impor-
tance. As a growing numbers of patients with NSCLC are
being treated with new chemotherapy agents known to cause
neutropenia, an increase in the number of neutropenia-related
complications such as typhlitis is expected.
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